{
  "ticker": "LLY",
  "target_date": "2025-02-19",
  "actual_date": "2025-02-19",
  "collected_at": "2025-12-08T11:25:30.738134",
  "price": {
    "open": 852.3,
    "high": 876.31,
    "low": 852.3,
    "close": 862.1139526367188,
    "volume": 3205500,
    "change_1d_pct": 1.15,
    "change_7d_pct": -1.11,
    "change_30d_pct": 11.07
  },
  "technicals": {
    "rsi_14": 68.83,
    "sma_20": 825.67,
    "sma_50": 794.53,
    "macd": 22.688,
    "macd_signal": 21.031,
    "macd_histogram": 1.658,
    "bb_upper": 900.92,
    "bb_lower": 750.42,
    "price_vs_sma20_pct": 4.41,
    "price_vs_sma50_pct": 8.51,
    "volume_ratio": 0.93
  },
  "fundamentals": {
    "market_cap": 891759362048,
    "pe_ratio": 48.738853,
    "forward_pe": 43.899384,
    "price_to_book": 37.453316,
    "price_to_sales": 15.007781,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.54,
    "pct_from_52w_low": 59.47
  },
  "macro": {
    "spy": {
      "price": 607.61,
      "change_1d_pct": 0.24,
      "change_7d_pct": 1.34
    },
    "vix": {
      "level": 15.27,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.53
    },
    "dollar_index": {
      "level": 107.17
    },
    "gold": {
      "price": 2919.4
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Why Novo Nordisk Is A Strong Buy Despite Market Concerns",
      "source": "SeekingAlpha",
      "datetime": 1740009540,
      "summary": "Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO stock a buy.",
      "url": "https://finnhub.io/api/news?id=3122007dae2978956606ea7a5228db0ac0ef5a4180bc8ae0df8c2091a0d4e554"
    },
    {
      "headline": "Eli Lilly Files For Mixed Shelf Size Not Disclosed - SEC Filing",
      "source": "Finnhub",
      "datetime": 1739987189,
      "summary": "Eli Lilly and Co: * ELI LILLY FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SECFILINGSource text:Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=c8e495d128de16023b8d488b3f4b95190c31515f4986072ea9626a9ef0f9d350"
    },
    {
      "headline": "Fat, not muscle: Drugmakers in race for next weight-loss breakthrough",
      "source": "Finnhub",
      "datetime": 1739959574,
      "summary": "Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound\u00a0result in both fat and muscle loss that can increase the...",
      "url": "https://finnhub.io/api/news?id=9681ac219bcf4501509d28ac8343888184676bfbcc65a2191036450c3f32074a"
    },
    {
      "headline": "Mairs & Power Balanced Fund Q4 2024 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1739954400,
      "summary": "The Fund lagged the benchmark composite index, which was up 15.01%, while the Fund underperformed the Morningstar Moderate Allocation peer group, which rose 11.29%.",
      "url": "https://finnhub.io/api/news?id=29975de5785e96be4bca83002c66233baf15555758fed17c910d511ee446c7b6"
    },
    {
      "headline": "IWLG: A Good Growth ETF, But Not The Best",
      "source": "SeekingAlpha",
      "datetime": 1739942917,
      "summary": "Discover key insights on IWLG, an actively managed ETF with tech focus. Explore its performance vs. SCHG and Russell 1000 Growth.",
      "url": "https://finnhub.io/api/news?id=3099b72d9aa5b1925798f85c189f26728a594a7ab6dcda9c824cf611e1b1ba6f"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740000210.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000077/xslF345X05/wk-form4_1740000210.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740000166.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000075/xslF345X05/wk-form4_1740000166.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740000116.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000073/xslF345X05/wk-form4_1740000116.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1739999917.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000071/xslF345X05/wk-form4_1739999917.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1739999835.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000069/xslF345X05/wk-form4_1739999835.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}